Current guidelines consequently note that single gene testing for the presence of RET fusions is not recommended on a stand-alone basis in patients with advanced NSCLC, but suggest that RET analysis should form part of any large multigene panel test developed for patients with lung cancer (1). Here, RET is linked to non-small cell lung carcinoma.